Fresh Equities
BARD1 LIFE SCIENCES LIMITED

BARD1 LIFE SCIENCES LIMITED

ASX:BD1

Last Placement
Bidding Closed
Offer Price
Not Available
Discount to Close
Not Available
Raised
$3.3M
Last Close
$0.0320
Market Cap at Close
Not Available
Relisted
Nov 8, 2018

Company Information

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian life sciences company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1’s proprietary technology platform is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes two development-stage BARD1 autoantibody tests for early detection of lung and ovarian cancers, and a research-stage cancer vaccine under evaluation for treatment of cancer. BARD1 is committed to transforming the early detection and prevention of cancer to help improve patients’ lives.

Type

Listed Company

GICS Sub-Industry

Health Care Services

Head Office

431 Roberts Rd, Subiaco WA 6008, Australia

Health Care Services
Health Care

Quarterly Cash Flows

The numbers below are derived from quarterly cash flow reports provided by the company. Fresh Equities does not guarantee that the information provided is accurate, you can read the associated report by clicking read more for the quarter. Always do your own research and do not rely on the information provided here as your only source of research.



Fresh Equities

Copyright © 2018 Fresh Equities. All rights reserved.

ACN 619 657 028. CAR: 001267539 of AFSL: 471379.
Archive
Support
This website does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other product or service by Fresh Equities Pty Ltd, its representatives or any other third party regardless of whether such security, product or service is referenced on this website.